Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > IF THIS DEAL GOES THROUGH........................

<< Previous

Bullboard Posts

Next >>

Post by RPINVESTOR1on Oct 23, 2024 7:38pm

95 Views

Post# 36279427

IF THIS DEAL GOES THROUGH........................

What is to prevent the PRIVATE COMPANY from selling the assets to a SECOND PRIVATE

COMPANY (same ownership) for say, $300,000., and have the shareholders of Replicel receive a total

payment of only $225,000. (ie. 75%)?

<< Previous

Bullboard Posts

Next >>

Nintendo stock jumps despite Q2 financials, new console news